Reported results
- Net revenue was $14.8 million for the first quarter of fiscal 2027, compared to $13.9 million for the prior-year period (GAAP).
- EXXUA net revenue was $4.9 million for the first quarter of fiscal 2027 (GAAP).
- ADHD Portfolio net revenue was $7.7 million for the first quarter of fiscal 2027, compared to $13.2 million in the prior-year period (GAAP).
- Pediatric Portfolio net revenue was $2.2 million for the first quarter of fiscal 2027, compared to $0.7 million in the prior-year period (GAAP).
- Net loss was ($3.9) million for the first quarter of fiscal 2027, compared to net income of $2.0 million in the prior-year period (GAAP).
- Adjusted EBITDA was ($2.6) million for the first quarter of fiscal 2027, compared to ($0.6) million in the prior-year period (non-GAAP).
Notes
The Company entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. on November 16, 2026, for $2.70 per share in cash.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
